---
title: Henry Schein (HSIC) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/hsic
ticker: HSIC
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Distribution
---
# Henry Schein (HSIC)

Henry Schein (HSIC) closed at $86.38 on Oct 16, 2026, overvalued by 4% vs its model value of $83.31 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $86.38 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $83.31 |
| Price vs model | overvalued by 4% vs model |
| Range of that model | $43.91 – $269.83 |
| Market value | $9.6B |
| P/E (fiscal 2025) | 26.4 |
| Net margin (fiscal 2025) | 3.0% |
| Free cash flow (fiscal 2025) | $573.0M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.84 |
| Cost of capital (WACC) | 7.60% |
| Business classification | Mature & Stable (Low/slowing growth (~3% recent), Thin margins (3.0% net margin), Highly cyclical earnings, Strong FCF yield (6.0%)) |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $83.31 | $43.91 | $269.83 |
| DCF · Perpetuity growth · 10y | cross check | $85.90 | $47.57 | $264.42 |
| DCF · EBITDA exit · 5y | cross check | $119.21 | $82.89 | $161.91 |
| DCF · EBITDA exit · 10y | cross check | $115.51 | $76.88 | $166.79 |
| P/E · peers | cross check | $118.33 | $108.82 | $187.05 |
| P/E · own history | cross check | $95.65 | $83.94 | $102.25 |
| PEG | sanity check | $114.50 | $114.50 | $114.50 |
| EV/EBITDA · peers | cross check | $122.40 | $95.90 | $126.65 |
| EV/Revenue · peers | cross check | $4.86 | $0.00 | $25.98 |
| Earnings power value | cross check | $42.25 | $31.29 | $58.62 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

No open-market insider buys or sales filed in the past 90 days.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 8, 2026 | Albertini Andrea | CEO,  Global Dist. & Tech. | Tax withholding | 603 | $53,582.6 |
| Sep 8, 2026 | Albertini Andrea | CEO,  Global Dist. & Tech. | Disposition to issuer | 3,984 | $0 |
| Jun 12, 2026 | DANIEL WILLIAM K | Director | Grant / award | 2,215 | $0 |
| May 26, 2026 | BERGMAN STANLEY M | Other | Bona fide gift | 50 | $0 |
| May 21, 2026 | BERGMAN STANLEY M | Director | Bona fide gift | 50 | $0 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 8, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1000228/000119312526417409/d159348d8k.htm |
| Sep 22, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1000228/000119312526397208/d110297d8k.htm |
| Aug 4, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1000228/000100022826000045/hsic-20260627.htm |
| Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1000228/000100022826000043/hsic-20260804.htm |
| Jul 30, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1000228/000119312526324857/d55491d8k.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Richard Pzena | 2026-06-30 | 860,733 | $71.9M |
| Einhorn | 2026-06-30 | 718,550 | $60.0M |
| Robert Olstein | 2026-03-31 | 74,000 | $5.5M |
| Bridgewater | 2026-06-30 | 58,993 | $4.9M |

5 tracked managers in all.

## About

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repa…

---

Source: https://sweetvaluelab.com/stocks/hsic (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.